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Introduction
Obsessive–compulsive disorder (OCD) is a neuropsychiatric 
disorder characterized by distressing, time-consuming or 
 impairing obsessions (recurrent thoughts, images or urges) 
and compulsions (repetitive behaviours or mental acts).1 Sev-
eral lines of evidence support the concept that dysfunctions 
of inhibitory control in frontostriatal circuits are associated 
with the inability to inhibit cognition and behaviour, as well 
as increased action-monitoring in people with OCD.2–4 
 Behavioural studies have shown that people with OCD have 
impaired motor and cognitive inhibitory mechanisms.5–7 
 People with OCD have shown impaired response inhibition 
in behavioural inhibition tasks such as the go/no-go task,5 
and young people with OCD have revealed deficits of behav-
ioural inhibition in an oculomotor task.6 In addition, neuro-
imaging studies have shown that excessive activation in spe-
cific brain regions, including the anterior cingulate and 
orbitofrontal cortices, in patients with OCD during trials 
 required response inhibition.8,9 Accumulating evidence has 
suggested that altered cortical inhibition, such as an imbal-
ance of direct and indirect feedback loops within cortical–
striatal–thalamic–cortical (CSTC) circuits, may contribute to 
the characteristic cognitive disruptions of OCD.2,10 An opto-
genetic mouse model has shown that stimulation in the 
fronto striatal pathway can alleviate OCD-relevant behav-
iours.11 These findings indicate that deficits in cortical inhibi-
tion in motor and cognitive processes may play a key role in 
the mechanisms of behavioural inhibition deficit and symp-
tom formation in patients with OCD.
Paired-pulse transcranial magnetic stimulation (TMS) is a 
noninvasive technique that allows researchers to directly 
 assess cortical excitability, which depends on the balance 
 between excitatory and inhibitory circuits. Paired-pulse TMS 
with subthreshold conditioning can test cortical excitability 
directly by measuring short-interval intracortical inhibition 
(SICI) at interstimulus intervals (ISIs) of 1 ms to 4 ms and in-
tracortical facilitation (ICF) at longer ISIs of 6 ms to 20 ms.12,13 
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Background: Deficits in cortical inhibitory processes have been suggested as underlying pathophysiological mechanisms of obsessive–
compulsive disorder (OCD). We examined whether patients with OCD have altered cortical excitability using paired-pulse transcranial 
magnetic stimulation (TMS). We also tested associations between TMS indices and OCD-related characteristics, including age of on-
set and response inhibition in the go/no-go paradigm, to examine whether altered cortical excitability contributes to symptom formation 
and behavioural inhibition deficit in patients with OCD. Methods: We assessed motor cortex excitability using paired-pulse TMS in 
51 patients with OCD and 39 age-matched healthy controls. We also assessed clinical symptoms and response inhibition in the go/no-
go task. All patients were undergoing treatment with serotonin reuptake inhibitors. We performed repeated-measures multivariate 
analy sis of covariance to compare TMS indices between patients with OCD and controls. Results: Compared to controls, patients with 
OCD showed a shorter cortical silent period and decreased intracortical facilitation. However, we found no significant difference 
 between groups for resting motor threshold or short-interval intracortical inhibition. In the OCD group, the shortened cortical silent 
 period was associated with a prompt reaction time in the go/no-go task and with early onset of OCD. Limitations: We could not 
 exclude the influence of medications on motor cortex excitability. Conclusion: These findings suggest abnormal cortical excitability in 
patients with OCD. The associations between cortical silent period and response inhibition and age of onset further indicate that 
 altered cortical excitability may play an important role in the development of OCD.
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A growing body of evidence suggests that SICI is mediated 
by γ-aminobutyric acid (GABA)-A receptors,14 while ICF 
 depends, in part, on glutamatergic neurotransmission.15,16 
Another key measure of TMS is the cortical silent period 
(CSP), which reflects GABA-mediated motor cortical post-
synaptic inhibition. It has been suggested that short CSPs 
elicited by low stimulus intensity are associated with the acti-
vation of GABA-A receptors, while long CSPs elicited by 
high stimulus intensity are associated with the activation of 
GABA-B receptors.17 These TMS parameters can be a promis-
ing neurophysiological biomarker for elucidating the under-
lying mechanisms of psychiatric disorders that involve 
 GABAergic and glutamatergic neurotransmission.
To date, inhibitory deficits and enhanced intracortical facil-
itation have been implicated in OCD, with a limited number 
of studies examining cortical excitability using paired-pulse 
TMS.18 One study reported that in a small OCD sample, 
 patients showed significantly reduced SICI and a decreased 
motor threshold compared with healthy controls.19 In con-
trast, a subsequent study in a healthy population reported 
that decreased SICI may be more linked to anxiety and 
 depression personality traits than to OCD itself.20 Another 
study in patients with OCD (n = 34) showed that OCD was 
associated with shortened CSP and increased ICF, and not 
associated with SICI, suggesting that dysregulation of 
GABA-B and N-methyl-d-aspartate (NMDA) receptor- 
mediated neurotransmission may be involved in the patho-
physiology of OCD.21
We aimed to investigate differences in cortical excitability 
between patients with OCD and healthy controls using 
paired-pulse TMS. We also examined associations between 
TMS indices and clinical characteristics — including age of 
onset and response inhibition in the go/no-go paradigm — 
to examine whether altered cortical excitability contributes 
to symptom formation and behavioural inhibition deficit in 
patients with OCD. We hypothesized that patients with 
OCD would have abnormal cortical excitability with 
 reduced resting motor threshold (RMT), shortened CSP, 
 reduced SICI or increased ICF and would show correlations 
between neurophysiological alteration and specific OCD-
related characteristics.
Methods
Participants
We recruited 55 patients with OCD from the OCD clinic in 
Severance Hospital and Yonsei Phil Neuropsychiatric Clinic, 
and 42 age-matched healthy controls via advertising. Partici-
pants underwent a face-to-face interview based on the Struc-
tured Clinical Interview for DSM-IV disorders.22 Inclusion 
criteria for the patient group were age 18 to 50 years, a cur-
rent DSM-IV diagnosis of OCD and stable maintenance of 
medication for at least 8 weeks before enrollment. Patients 
with comorbid depression but without psychotic features 
were included in the study only if the obsessive–compulsive 
symptoms were their most prominent symptoms and the 
 onset of OCD predated the onset of depression. Controls 
were included if they had been physically healthy and 
 medication-free for the past 6 months, had no history of 
psychi atric disorders (including OCD and depressive disor-
ders) and no family history of psychiatric disorders among 
first-degree relatives. All participants were right-handed. 
Participants were excluded if they presented with a move-
ment disorder other than a tic; any psychotic symptoms; 
other anxiety disorders; an intellectual disability; alcohol or 
other substance abuse within the last 6 months; or a history 
of seizure, psychosurgery, encephalitis or significant head 
trauma. The study was approved by the ethical committee of 
Severance Hospital, and written informed consent was 
 obtained from all participants.
Among the recruited participants, 2 patients and 2 controls 
with comorbid psychiatric problems were excluded. Two 
 patients and 1 control who felt uncomfortable during the TMS 
procedure and wanted to stop participation (2 headache, 
1 nonspecific discomfort) were also excluded because of 
 incomplete acquisition of TMS data. Ultimately, 51 patients 
with OCD (mean age ± standard deviation = 27.43 ± 7.64 years) 
and 39 age-matched healthy controls (27.36 ± 6.99 years) were 
included in our analyses. The present sample exceeded the rec-
ommended sample size of 34 in each group required to detect 
the global effect with medium effect size in a multivariate 
analy sis of variance according to G*Power.23
TMS protocol and stimulation parameters
For TMS, we used 2 Magstim-200 stimulators connected via a 
Bistim module with a 70 mm figure-8 coil (Magstim Com-
pany Ltd.). We took TMS recordings with surface electrodes 
from the abductor digiti minimi muscle. The coil was held 
with the grip pointing backward and perpendicular to the 
central sulcus. For optimal coil positioning, we measured the 
amplitudes of the motor evoked potential in the resting 
 abductor digiti minimi by moving the coil in 1 cm steps over 
the presumed area of the contralateral motor cortex. We per-
formed the paired-pulse paradigms on both hemispheres.
For measures of motor cortex excitability, we examined 
motor evoked potential, RMT, CSP, SICI and ICF. We deter-
mined RMT over the primary motor cortex in both groups by 
finding the minimal intensity required to elicit at least 
5 motor evoked potentials of 50 mV out of 10 stimulations of 
the contralateral abductor digiti minimi muscle.
We obtained CSP by applying stimuli with an intensity of 
40% above the active motor threshold. We applied and recorded 
TMS pulses with 10 trials at 140% of the active motor threshold 
during a low-level voluntary contraction of the abductor digiti 
minimi muscle. The duration of the CSP was defined in the rec-
tified single trials as being from the end of the preceding motor 
evoked responses to the return of the amplitude of the mean 
voluntary electromyographic activity before TMS. The dura-
tions of each CSP elicited from 10 consecutive electromyo-
graphic signals were rectified and then averaged.
We used paired-pulse TMS with subthreshold condition-
ing to test SICI with ISIs of 2 ms and 3 ms and ICF with ISIs 
of 10 ms and 15 ms. The conditioning stimulus was set at 80% 
of the RMT and preceded the test stimulus (110% to 120% of 
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the RMT), which produced a response of about 1 mV peak-
to-peak amplitude. We applied 10 paired-pulse TMS trials of 
each ISI in 4 randomly intermixed conditions. Time between 
trials was 5 s. We measured the peak-to-peak amplitudes and 
then averaged them.
Measures of clinical symptoms and traits
We assessed all participants for obsessive–compulsive symp-
toms using the Maudsley Obsessional Compulsive Inventory 
(MOCI).24 The MOCI is a self-rating instrument of 30 dichoto-
mous items designed to measure obsession and compulsion 
symptoms. It consists of 4 subscales: checking, washing, 
doubting and slowness. We also assessed patients with OCD 
using the Yale–Brown Obsessive Compulsive Scale (Y-BOCS)25 
for the severity of obsessive–compulsive symptoms. We 
 assessed depressive symptoms and anxiety levels using the 
Montgomery–Åsberg Depression Rating Scale (MADRS)26 and 
the Hamilton Anxiety Rating Scale (HARS),27,28 the most 
widely used semi-structured assessment scales, administered 
by trained psychiatrists. Missing values below 5% were 
 replaced by an expectation-maximization algorithm.
Go/no-go test
To measure motor response inhibition, we performed the 
computerized go/no-go test (a faster variant of the classical 
go/no-go paradigm) in patients with OCD.5 We have previ-
ously reported impaired response inhibition in patients with 
OCD compared with healthy controls, using the go/no-go 
test.29 The task requires selection of a response (indicated by a 
“go” signal) or no response (indicated by a “no-go” signal). 
Patients with OCD were asked to respond to go signals (air-
planes) appearing on the centre of the screen but not to no-go 
signals (bombs). The task was administered in 2 blocks, with 
90 practice trials and 180 testing trials (126 go trials and 
54 no-go trials) in randomized order. Patients were asked to 
inhibit their motor response when the no-go signals 
 appeared on the screen. The ISI was 1000 ms, including a 
stimulus duration of 200 ms followed by a blank screen for 
800 ms. The dependent variables of the inhibitory process 
were the percentage of successful inhibition trials and the 
mean reaction time for the correct go trials (ms).
Statistical analysis
We performed a priori power analysis using G*Power 3.1.23 A 
sample size of 68 participants (minimum 34 in each group) 
was needed to potentially detect a global effect of multivari-
ate analysis of variance with a medium effect size (f2V = 0.25), 
a power of 0.9 and 4 response variables.
We analyzed data using SPSS 23.0 for Windows (SPSS 
Inc.). Significance was set at p < 0.05. All tests were 2-tailed. 
We used the t test to evaluate differences in demographic 
and clinical characteristics between groups for continuous 
variables and χ2 tests for categorical variables.
We performed repeated-measures multivariate analysis 
of covariance (MANCOVA) to compare neurophysiological 
indices of TMS between patients with OCD and healthy 
controls, with hemisphere (left v. right) as the repeated fac-
tor, group (OCD v. controls) as the between-subjects factor, 
and TMS indices of RMT, CSP, SICI and ICF as the within-
subjects factors. In MANCOVA, we used the mean values 
of the conditioned motor evoked potential size (a ratio of 
the conditioned motor evoked potential amplitude to the 
control motor evoked response) at ISIs of 2 ms and 3 ms as 
the parameter for SICI, and 10 ms and 15 ms for ICF. 
 Covariates included age30 and sex31 to remove any possible 
effects on cortical excitability, based on previous findings. 
Significant results from MANCOVA were followed by sepa-
rate univariate ANCOVA. We calculated ηp2 values as a 
measurement of effect size, considering that a ηp2 of 0.01 
was small, 0.04 moderate and 0.1 large.32 For post-hoc 
 ANCOVA, we adjusted the significance threshold using a 
Bonferroni approach to correct for tests of 4 dependent vari-
ables (i.e., 0.05/4 = 0.0125).
We also used partial correlations (pr) with covariates to 
explore the relationships between neurophysiological indi-
ces and clinical variables, such as onset age and parameter, 
regarding the inhibitory function on the go/no-go test 
(mean reaction time on the correct go trials) in patients 
with OCD.
Results
We found no significant differences between patients with 
OCD and controls in terms of age, sex or educational level. 
All patients were undergoing treatment with serotonin reup-
take inhibitors (SRIs). Clinical characteristics are presented 
in Table 1.
Repeated-measures MANCOVA with hemisphere (left v. 
right) as the repeated factor, diagnostic status of OCD as a 
between-subjects factor, age and sex as covariates, and TMS 
variables (RMT, CSP, ICF and SICI) as the within-subjects 
factors showed a significant difference between patients with 
OCD and healthy controls (F4,83 = 10.66; p < 0.001; ηp2 = 0.339). 
We found no significant main effect of hemisphere (left v. 
right; F4,83 = 1.140; p = 0.34). We also observed no significant 
interaction effects between age and hemisphere (F4,83 = 0.555; 
p = 0.70), sex and hemisphere (F4,83 = 1.542; p = 0.20) or OCD 
diagnosis and hemisphere (F4,83 = 0.722; p = 0.58). In post hoc 
between-group comparisons, patients with OCD showed sig-
nificantly shortened CSP compared to healthy controls (F1 = 
12.604; p = 0.001; ηp2 = 0.128; Fig. 1). Patients with OCD also 
had significantly decreased ICF (F1 = 10.298; p = 0.002; ηp2 = 
0.107). We found no significant difference in SICI (F1 = 3.879; 
p = 0.052; ηp2 = 0.043) or RMT (F1 = 0.073; p = 0.79) between 
groups (Fig. 1).
After excluding patients with comorbid depression (n = 
21), MANCOVA with the OCD group (n = 30) also showed 
that the between-group effects of CSP (F = 5.678; p = 0.020; 
ηp2 = 0.080) and ICF (F = 11.798; p = 0.001; ηp2 = 0.154) were 
still meaningful.
In the partial correlation analyses with age and sex as 
 covariates, we found positive correlations at the trend level 
between CSP and mean reaction time in the go/no-go test 
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(pr = 0.280; p = 0.051) and age of onset (pr = 0.285; p = 0.047; 
Fig. 2). When we included the MADRS score as a further 
 covariate in partial correlations (because depressive symp-
toms may affect performance in the go/no-go task), the cor-
relation between CSP and mean reaction time was significant 
(pr = 0.358; p = 0.013). On the other hand, we found no sig-
nificant correlations between other neurophysiological indi-
ces of TMS and clinical symptom scores of OCD as measured 
by MOCI, Y-BOCS, MADRS or HARS.
Discussion
The present study examined cortical excitability using 
paired-pulse TMS in patients with OCD and healthy controls 
to elucidate cortical inhibitory deficits in OCD. To our know-
ledge, it involves the largest sample of patients with OCD 
among studies using the paired-pulse TMS paradigm. Our 
results show that compared with controls, patients with OCD 
had altered cortical excitability in terms of shortened CSP 
and decreased ICF. We found no significant differences in 
RMT and SICI between patients with OCD and controls. 
These findings suggest that alterations of inhibitory neuro-
transmission mediated by GABA-B receptors and excitatory 
neurotransmission mediated by NMDA receptors may be 
 involved in the pathophysiology of OCD.
Our finding of shortened CSP, a major inhibitory index, in 
OCD was consistent with previous results.19,21,33 Furthermore, 
in our correlation analyses, shortened CSP was associated 
with prompt reaction time in a go/no-go task and early onset 
of OCD. In particular, after adjusting for depressive symp-
toms, the correlation between CSP and reaction time in the 
go/no-go task was significant (p = 0.013). Shortened CSP in 
patients with OCD along with a shorter reaction time in go 
trials may indicate that the neurophysiological mechanism of 
impaired cortical inhibition plays a crucial role in impaired 
inhibitory control of thoughts and behaviours in OCD. In ad-
dition, because CSP at high stimulus intensity is considered a 
marker of GABA-B receptor-mediated inhibitory function,34 
these findings in patients with OCD suggest that a lack of 
cortical inhibition via GABA-B receptor-mediated dysregula-
tion might contribute to response inhibition and acceleration 
of OCD onset. However, since the present study had a cross-
sectional design, further prospective research is needed to 
prove a possible association for OCD onset and response 
inhibition.
Regarding SICI, another main inhibitory parameter of 
TMS, our results did not show any significant finding of 
 reduced cortical inhibition in patients with OCD compared 
with controls. This finding was consistent with that of Richter 
and colleagues,21 who found no differences between patients 
with OCD (n = 34) and healthy controls. However, it was 
 inconsistent with a recent finding by Khedr and colleagues,33 
which showed that patients with OCD (n = 45) had signifi-
cantly reduced SICI compared with healthy controls. 
 Greenberg and colleagues19 also showed that SICI in patients 
with OCD (n = 16) was significantly lower than in healthy 
controls. These discrepancies may have been partially due to 
the low statistical power of small sample sizes and medica-
tion effects. Since SRIs are known to modulate GABA 
 release35 and enhance SICI,36 the possible effect of SRIs could 
have concealed any potential SICI deficits in the current 
study. To confirm the characteristics of cortical excitability in 
OCD, replication by future studies using paired-pulse TMS 
in larger samples with drug-naive patients is needed.
Contrary to our expectations, for the facilitatory compon-
ent of intracortical excitability, patients with OCD had 
Table 1: Demographic and clinical characteristics between patients with OCD and healthy controls*
Characteristic
Healthy controls
(n = 39)
OCD
(n = 51) t or χ2 p value
M/F, n 30/9 40/11 0.029 0.87
Education, yr 14.10 ± 2.00 13.41 ± 2.19 –1.54 0.13
MOCI score 4.61 ± 2.67 17.49 ± 5.90 13.85 < 0.001
Age of OCD onset, yr — 15.90 ± 5.80 — —
Y-BOCS score — 23.51 ± 7.23 — —
MADRS score — 16.94 ± 10.02 — —
HARS score — 14.45 ± 9.95 — —
Comorbid depression, n 0 21 — —
Receiving SRIs, n 0 51† — —
Concomitant medications
Benzodiazepines, n 0 28‡ — —
Antipsychotics, n 0 4§ — —
Go/no-go task
Successful inhibition trials, % — 84.51 ± 9.76 — —
Reaction time for go trials, ms — 300.84 ± 49.75 — —
HARS = Hamilton Anxiety Rating Scale; MADRS = Montgomery–Åsberg Depression Rating Scale; MOCI = Maudsley Obsessional Compulsive 
Inventory; OCD = obsessive–compulsive disorder; SRI = serotonin reuptake inhibitor; Y-BOCS = Yale–Brown Obsessive Compulsive Scale. 
*Data shown as mean ± standard deviation unless otherwise specified. All tests were 2-tailed.
†Escitalopram 10~40 mg/d: 16; fluoxetine 40~100 mg/d: 15; paroxetine 37.5~87.5 mg/d: 9; sertraline 100~200 mg/d: 7; fluvoxamine 200~400 mg/d: 4.
‡Lorazepam-equivalent dose: 1.198 mg/d.
§Quetiapine 25 mg/d, 1; quetiapine 50 mg/d, 2; aripiprazole 5 mg/d, 1.
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 significantly decreased ICF compared with healthy controls, 
indicating reduced glutamatergic signalling in OCD. The 
 effect size of decreased ICF was greater after excluding 
 patients with comorbid depression (ηp2 = 0.154). Conversely, 
Greenberg and colleagues19 reported higher mean values for 
ICF in OCD than in controls, although this difference did not 
reach significance. Richter and colleagues21 also showed that 
patients with OCD had greater ICF than healthy controls. As 
well, mixed findings have been observed for levels of cortical 
glutamate transmission in patients with OCD.37,38 These 
 inconsistent findings may be partially explained by the clin-
ical heterogeneity of OCD, medication effects, limited statis-
tical power and the different phase of treatment courses 
across studies. Although the findings remain inconclusive, 
the altered ICF observed in patients with OCD might reflect a 
disrupted neuroplasticity via altered glutamate-mediated 
 excitatory neurotransmission in OCD. Evidence from TMS 
studies in depressive patients suggests that reduced facilita-
tion and impaired glutamate-mediated neuroplasticity in 
 response to paired associative stimulation are implicated in 
depression and cognitive dysfunction.39,40 Further research is 
required to confirm the present findings and to gain a better 
understanding of alterations in cortical excitability and 
neuro plasticity in patients with OCD.
Fig. 1: Motor cortical excitability between patients with OCD and healthy controls. Graph showing variable means of bilateral RMT, CSP, ICF 
and SICI amplitudes in patients with OCD (n = 51) and controls (n = 39). Error bars represent ± 1 standard error of the mean. CSP = cortical 
silent period; ICF = intracortical facilitation; MEP = motor evoked potential; OCD = obsessive–compulsive disorder; RMT = resting motor 
threshold; SICI = short-interval intracortical inhibition. 
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Together, our findings of altered CSP and ICF provide fur-
ther neurophysiological evidence for an imbalance in inhibi-
tory and excitatory function in the cortical circuits of patients 
with OCD. This imbalance is also supported by substantial 
 evidence from functional imaging studies, which have shown 
the involvement of CSTC circuits in OCD.4,41,42 Within the 
CSTC circuitry, the interactive loop between the GABA ergic 
inhibitory and glutamatergic excitatory pathways is thought to 
be responsible for balancing neural tone.4,38 Genetic studies 
have also shown the involvement of genes related to GABA or 
glutamate in OCD pathogenesis.43–45 The imbalance of 
 GABAergic and glutamatergic receptor–mediated neurotrans-
mission in CSTC circuitry may contribute to the regional 
 hyperactivity and lack of response inhibition seen in OCD, 
leading to obsessive–compulsive symptoms.
Limitations
Several limitations should be mentioned. First, although there 
was no difference in the degree of SICI between medicated 
and unmedicated patients in previous studies,19,33 we cannot 
exclude the influence of medications on motor cortex excitabil-
ity. All patients in the present study were undergoing SRI 
treatment, and some were on concomitant benzodiazepines or 
antipsychotics. Alterations in TMS measures produced by 
medication have been reported to be complex depending on 
the individual drug and chronic use: a single dose of citalo-
pram enhances CSP and SICI, whereas chronic paroxetine use 
does not alter either CSP or SICI but enhances ICF.46 In addi-
tion, benzodiazepines enhance SICI and reduce ICF, whereas 
dopamine antagonists, such as antipsychotics, increase ICF.47 
For paired-pulse TMS measurements, medications influencing 
GABA, glutamate, serotonin or dopamine neurotransmission35 
could affect GABAergic and glutamatergic receptor-mediated 
neurotransmission in CSTC circuitry and neuroplasticity.47,48 
Second, the limited sample size may make it difficult to draw 
definitive conclusions, because low statistical power may lead 
to increased rates of false negatives and false positives. Third, 
since a role for the GABAergic and glutamatergic system has 
also been reported in the pathophysiology of depression, 
 comorbid depression may have biased the present results. 
Previous TMS studies have shown that patients with depres-
sion had reduced excitability of both inhibitory and facilita-
tory inputs compared with controls.49,50 However, our results 
of shortened CSP and decreased ICF still remained significant 
after excluding individuals with comorbid depression. The 
correlation between CSP and response inhibition on the go/
no-go task was also significant after adjusting for depressive 
symptoms. Therefore, we believe that the findings of altered 
cortical excitability may be specifically related to OCD, rather 
than depression. Fourth, this study is limited by the lack of 
neuroradiological imaging and of estimates of peripheral 
nerve excitability and central motor conductivity. Finally, we 
examined TMS indices of cortical excitability only in the motor 
cortex, which may not be relevant to key brain regions of 
OCD. Measurements of cortical excitability in brain regions 
critically involved in OCD may be helpful for understanding 
the underlying pathophysiology of OCD.
Fig. 2: Correlation between CSP and mean reaction time for the correct go trials in the go/no-go task and age at onset in patients with OCD 
(n = 51). CSP = cortical silent period; OCD = obsessive–compulsive disorder. 
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Conclusion
The present study showed that patients with OCD had  altered 
cortical excitability with shortened CSP and decreased ICF. In 
addition, the associations between CSP and response inhibi-
tion and onset age further suggest that cortical inhibition may 
be involved in the pathophysiology of OCD. Our findings sup-
port the role of altered cortical excitability in contributing to 
symptom formation in OCD. Further research in larger sam-
ples that include unmedicated patients is warranted to eluci-
date the pathophysiology of OCD.
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